Vaccines have saved millions of lives, but nobody likes getting a shot. That’s why scientists are trying to develop oral vaccines for infectious diseases.
But to be effective, the vaccine must survive digestion and reach immune cells within the intestinal wall. Now, researchers reporting in the ACS journal Nano Letters have developed oral vaccines powered by micromotors that target the mucus layer of the intestine.
In addition to avoiding needles, oral vaccines can generate a broader immune response by stimulating immune cells within the mucus layer of the intestine to produce a special class of antibody called immunoglobulin A (IgA). Joseph Wang, Liangfang Zhang and colleagues wondered if they could use magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus. When coated over most of their surfaces with titanium dioxide, magnesium microparticles use water as fuel to generate hydrogen bubbles that power their propulsion.
To develop the oral vaccine, the researchers coated magnesium micromotors with red blood cell membranes that displayed the Staphylococcal ?-toxin, along with a layer of chitosan to help them stick to the intestinal mucus. Then, they added an enteric coating that protects drugs from the acidic conditions of the stomach. When given orally to mice, the micromotors safely passed through the stomach, and then the enteric coating dissolved, activating the motors. Imaging of mice that had been given the vaccine showed that the micromotors accumulated in the intestinal wall much better than non-motorized particles. The micromotors also stimulated the production of about ten times more IgA antibodies against the Staphylococcal ?-toxin than the static particles.
Learn more: Micromotors deliver oral vaccines
The Latest on: Oral vaccines
via Google News
The Latest on: Oral vaccines
- Florida judge denies business from requiring COVID-19 vaccineon October 14, 2021 at 11:33 pm
A Leon County circuit court judge denied a request from a Sarasota business to allow it to require customers be vaccinated, upholding a state law championed by Gov. Ron ...
- Florida judge denies Sarasota business’ request to allow COVID-19 vaccine requirementon October 14, 2021 at 11:33 pm
A Leon County circuit court judge denied a request from a Sarasota business to allow it to require customers be vaccinated, upholding a state law championed by Gov. Ron DeSantis banning ...
- Hearing for Syosset nurses fighting vaccine mandate delayed until Oct. 27on October 14, 2021 at 10:18 pm
Two Syosset nurses will have to wait longer to make their cases against New York’s vaccine mandate to a federal appeals panel.
- 2nd Circuit Seems Likely to Uphold City's Vaccine Mandate for Public School Teacherson October 14, 2021 at 4:18 pm
Judges indicated during oral arguments that city officials had a rational basis for requiring teachers and other workers to be vaccinated against COVID-19 or be barred from public school buildings.
- Federal judge hears arguments over 4 Charleston-area governmental vaccine mandateson October 14, 2021 at 1:30 pm
Lawyers representing over 100 Charleston-area municipal employees challenging local vaccination mandates argued Oct. 14 the matters at hand are guaranteed federal and state rights, and not the vaccine ...
- Global Therapeutic Proteins and Oral Vaccines Market 2021 Research Study with Trends and Opportunities to 2027 - Impact of COVID-19on October 13, 2021 at 2:06 pm
Another report by named, Global Therapeutic Proteins and Oral Vaccines Market 2021 by Company, Regions, Type and Application, Forecast to 2027 has been added into its tremendous archive by ...
- Cost of Merck COVID-19 Pill: How Treatment Compares to Vaccines, Monoclonal Antibodieson October 12, 2021 at 10:56 am
Merck's COVID-19 oral antiviral pill would be a cheaper solution to outpatient therapeutics than monoclonal antibody treatments, but it's still 17 times more expensive than getting vaccinated against ...
- Oral and intranasal COVID-19 vaccines show promising results in hamster modelon October 8, 2021 at 6:22 am
A new preprint discusses the protective effect of an oral adenovirus-vectored vaccine based on the SARS-CoV-2 spike against viral transmission and disease in hamsters.
- Vaxart’s Oral COVID-19 Vaccine Reflects Optimism; Shares Riseon October 8, 2021 at 4:57 am
Shares of Vaxart Inc. (VXRT) rose 8.74%, at the time of writing, in early trade on Friday. The stock price moved after a Duke University-led study ...
- Vaxart starts subject enrolment in trial of oral vaccine for Covid-19on October 7, 2021 at 2:58 am
Approximately 96 subjects in the US will be given the vaccine as part of the trial this month. Vaxart has commenced participant recruitment in the Phase II clinical trial of S-only oral tablet vaccine ...
via Bing News